Recent studies showed that the improved LCK activity was contributed to improve the efficacy of chimeric antigen receptors (CARs) immunotherapy in cancers (Gulati et al., 2018; Bommhardt et al., 2019; Suryadevara et al., 2019). The gene discussed is LCK; the disease is cancer.